Ankündigung • Apr 01
4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million. 4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 14,067,797
Price\Range: AUD 5.9
Discount Per Security: AUD 0.236
Transaction Features: Subsequent Direct Listing Ankündigung • Mar 30
4Dmedical Limited Announces Commercial Launch of CT:VQ Imaging Technology in European Union 4DMedical Limited announced that its latest imaging technology, CT:VQ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets. CT:VQ is the world's first and only non-contrast, ventilation-perfusion imaging technology, providing quantitative functional lung insights from routine non-contrast CT scans without the need for radiotracers or specialised nuclear medicine infrastructure. Pulmonary disease is fundamentally functional—defined by abnormalities in ventilation and perfusion—yet most routine imaging available to radiologists and pulmonologists remains purely structural. CT:VQ bridges that gap by generating ventilation and perfusion maps allowing clinicians to visualize regional lung function with the anatomical clarity of CT. For large medical institutions, CT:VQ is designed to fit within existing CT-based workflows and infrastructure. CT:VQ offers relief from long-standing constraints associated with conventional nuclear VQ imaging, including radiotracer availability, workforce limitations and operational complexity. The European market represents a significant opportunity for advanced cardiothoracic imaging. With a population of more than 450 million, a highly developed hospital-based imaging infrastructure and an extensive installed base of CT scanners, the EU is well positioned for adoption of CT-based functional lung imaging. 4DMedical estimates that approximately 400,000 nuclear VQ scans are performed annually across the EU, underscoring the scale of clinical need. The CE Mark follows growing U.S. momentum for CT:VQ, which is now deployed at six leading academic medical centres: Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, University of Chicago Medicine, and the recently announced initial deployment at Mayo Clinic. 4DMedical believes this early adoption by major U.S. institutions demonstrates strong interest in CT:VQ among leading radiology and pulmonary teams and provides a blueprint for expansion into Europe. 4DMedical said it is now advancing plans to expand commercial engagement across Europe and to work with leading hospitals and clinicians on adoption, evaluation and research initiatives for CT:VQ. CT:VQ is 4DMedical's proprietary ventilation-perfusion imaging solution that generates functional lung information from non-contrast CT scans. Built on the Company's patented XV Technology, CT:VQ is designed to provide quantitative ventilation and perfusion insights within familiar CT workflows, without requiring radiotracers. Ankündigung • Mar 27
4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million. 4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 14,067,797
Price\Range: AUD 5.9
Discount Per Security: AUD 0.236
Transaction Features: Subsequent Direct Listing Ankündigung • Jan 15
4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million. 4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,806,185
Price\Range: AUD 3.8
Discount Per Security: AUD 0.19 Ankündigung • Dec 20
4DMedical Limited Announces John Livingston Reverts to Non-Executive Director Position, Effective 1 January 2025 4DMedical Limited announced that Director John Livingston is to revert to a Non-Executive Director position with the Company, effective 1 January 2025. John's terms of appointment as a non-executive director will be on the same basis as other non-executive directors. Ankündigung • Sep 24
4DMedical Limited, Annual General Meeting, Nov 20, 2024 4DMedical Limited, Annual General Meeting, Nov 20, 2024. Ankündigung • Dec 16
4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million. 4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 44,303,797
Price\Range: AUD 0.79
Discount Per Security: AUD 0.0395
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Ankündigung • Dec 11
4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million. 4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 44,303,797
Price\Range: AUD 0.79
Discount Per Security: AUD 0.0395
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Ankündigung • Nov 23
4DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software 4DMedical has received FDA clearance for its CT-based ventilation product (CT LVAS(TM). CT LVAS, designed for use with computed Tomography scans, joins 4D Medical's XV LVAS(R) imaging software cleared for use with fluoroscopy In the United States. The FDA clearance for CT LVAS dovetails with the upcoming 4DMedical product, CT:VQ(TM). CT:VQ will enable quantitative perfusion (blood flow) data and visualizations to be extracted from CT scans. Standard CT images provide clinicians with structural detail about patients' lungs--from which they try to inferred information about disease and function. CT LVAS adds a wealth of data on lung performance on top of the structural detail of CT scans. This capability fills an information gap that enables radiologists to provide the objective, data-driven information that could materially inform diagnosis and treatment options. CT LVAS software processes existing CT scans using sophisticated algorithms derived from aerospace technology. These highly detailed reports include color-coded images of regional airflow and lung ventilation--overlayed on the patient's CT scan. CT LVAS uses a software-as-a-service model and requires no new capital equipment. Scans from existing CT equipment are uploaded for processing, where they are analyzed and returned to the radiologist as the Ventilation Report. CT LVAS measures lung ventilation in tens of thousands of locations in the lungs. The Regional Ventilation Visualizations provide region-specific ventilation at deep inspiratory breath-hold for a mid-coronal slice and threeaxial slices--Upper, Middle, and Lower. The regional ventilation data is quantified in lung volume change and regional lung ventilation heterogeneity. Ankündigung • Nov 01
4DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee 4DMedical Limited announced that Evonne Collier has resigned as a non-executive director, Chair of the Remuneration and Nomination Committee. Ankündigung • Sep 25
4DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors 4DMedical Limited announced the appointment of Dr. Geraldine McGinty, MD, to the Company’s Board of Directors. Professor of Clinical Radiology and Population Health Sciences, and a certified radiologist practising at Weill Cornell Medical Center, Dr. McGinty is an accomplished academic, researcher, administrator and health care economist. In 2018, Dr. McGinty became the first woman elected as Chair of the American College of Radiology’s (ACR) board of Chancellors, making a significant contribution to the ACR through a reorganisation of its Data Science Institute, enabling greater board communication and diversity of opinion. The ACR is "The Voice of Radiology" in matters of legislation and regulation, and is responsible for guiding radiology reimbursement and coding issues, including relative value units, managed care, alternative payment models, and Medicare regulations. Prior to this, Dr. McGinty headed up the ACR’s Commission on Economics. The Commission’s work often is used as background material and evidence for ACR congressional and state legislative efforts as well as communications with the CMS (Centers for Medicare & Medicaid Services), policy makers, and other medical insurers. Her corporate governance experience includes serving on the Board of NextGen Healthcare, and as a Non-Executive Director with the Industrial Development Authority (IDA) of the Republic of Ireland, chairing its Audit, Risk and Finance Committee. Dr. McGinty is also a member of the Governing Authority of the University of Galway in Ireland. In her various leadership roles, Dr. McGinty has been a powerful and influential voice for women in medical imaging. She has also been instrumental in identifying and mentoring radiologists who push to address health disparities in research, advocacy efforts, artificial intelligence development, and medical student recruitment. Dr. McGinty is highly qualified in clinical practice and management, possessing both a medical degree from the National University of Ireland and a master’s degree in business administration from Columbia University. Dr. McGinty’s academic stature is reflected in her appointment as Professor of Clinical Radiology at Weill Cornell Medicine where she is concurrently Senior Associate Dean of Clinical Affairs. In 2017, Dr. McGinty was appointed as founding Academic Director for the Executive MBA and Masters in Healthcare Leadership program delivered jointly by Weill Cornell and the Cornell University SC Johnson School of Business, a role she performed until 2019. Dr. McGinty’s published work has focused on payment models for imaging, most recently a bundled payment for breast cancer screening. Recently she has focused on the impact of Artificial Intelligence on Medical Imaging and has spoken at the Turing Institute and to the WHO Focus Group on AI in Healthcare on this topic. As a member of the American Medical Association’s Relative Value Unit Update Committee from 2012- 2016, Dr. McGinty was instrumental in recommending reimbursement policy to Medicare, thereby impacting the economics of the entire U.S. healthcare delivery system. In addition, from 2015 to 2021, Dr. McGinty was Chief Strategy and Contracting Officer within Weill Cornell responsible for fee-for-service and value-based payment arrangements. Ankündigung • Aug 29
4DMedical Limited, Annual General Meeting, Nov 02, 2023 4DMedical Limited, Annual General Meeting, Nov 02, 2023, at 10:00 AUS Eastern Standard Time. 
